Expression of a large, nontoxic fragment of botulinum neurotoxin serotype A and its use as an immunogen.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Toxicon

• Publication date

  1995-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/0041-0101(95)00072-TPMID 8599190
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Contributions of the U.S. Army to Botulinum Toxin Research

  1993cited by this paper
• Clostridial neurotoxins--proposal of a common nomenclature.

  1992cited by this paper
• The complete amino acid sequence of the Clostridium botulinum type A neurotoxin, deduced by nucleotide sequence analysis of the encoding gene.

  1990cited by this paper
• Expression of Tetanus Toxin Fragment C in E. coli: Its Purification and Potential Use as a Vaccine

  1989cited by this paper
• Expression of tetanus toxin fragment C in E. coli: high level expression by removing rare codons.

  1989cited by this paper
• Botulinum neurotoxin and tetanus toxin

  1989cited by this paper
• Immunization of mice against tetanus with fragments of tetanus toxin synthesized in Escherichia coli

  1987cited by this paper

• Recent Developments in Vaccine Design: From Live Vaccines to Recombinant Toxin Vaccines

  2023cites this paper
• High Cell Density Cultivation Process for the Expression of Botulinum Neurotoxin a Receptor Binding Domain

  2022cites this paper
• Enhancing toxin-based vaccines against botulism.

  2018cites this paper
• Vaccines against Botulism

  2017cites this paper
• Antigenic sites on the HN domain of botulinum neurotoxin A stimulate protective antibody responses against active toxin

  2015cites this paper
• Expression, purification and characterization of the receptor-binding domain of botulinum neurotoxin serotype B as a vaccine candidate.

  2015cites this paper
• In Vivo BoNT/A and BoNT/E Intoxications Neurotoxin Serotype A (BoNT/A) Inhibits The Receptor Binding Domain of Botulinum

  2014cites this paper
• Recombinant Vaccine Candidate as a Pichia pastoris Domain from Botulinum Neurotoxin Type A Binding Purification, Potency, and Efficacy of the

  2014cites this paper
• High level expression, purification and immunogenicity analysis of a protective recombinant protein against botulinum neurotoxin type E

  2014cites this paper
• High level expression, purification and immunogenicity analysis of a protective recombinant protein against botulinum neurotoxin type E

  2014cites this paper
• Easy expression of the C-terminal heavy chain domain of botulinum neurotoxin serotype A as a vaccine candidate using a bi-cistronic baculovirus system.

  2013cites this paper
• The Receptor Binding Domain of Botulinum Neurotoxin Serotype A (BoNT/A) Inhibits BoNT/A and BoNT/E Intoxications In Vivo

  2013cites this paper
• The Receptor Binding Domain of Botulinum Neurotoxin A Inhibits Botulinum A

  2013cites this paper
• High level expression of recombinant BoNT/A-Hc by high cell density cultivation of Escherichia coli

  2012cites this paper
• Medical Applications of Clostridia and Clostridial Toxins

  2012cites this paper
• Sheep Monoclonal Antibodies Prevent Systemic Effects of Botulinum Neurotoxin A1

  2012cites this paper
• Recombinant botulinum neurotoxin A heavy chain-based delivery vehicles for neuronal cell targeting.

  2011cites this paper
• Retargeting Clostridium difficile Toxin B to Neuronal Cells as a Potential Vehicle for Cytosolic Delivery of Therapeutic Biomolecules to Treat Botulism

  2011influential citation
• Immunogenic and protective potentials of recombinant receptor binding domain and a C-terminal fragment of Clostridium botulinum neurotoxin type E

  2011cites this paper
• Immunization of mice with the non-toxic HC50 domain of botulinum neurotoxin presented by rabies virus particles induces a strong immune response affording protection against high-dose botulinum neurotoxin challenge.

  2011cites this paper
• Improved soluble expression and characterization of the Hc domain of Clostridium botulinum neurotoxin serotype A in Escherichia coli by using a PCR-synthesized gene and a Trx co-expression strain.

  2010cites this paper
• Mode of action of botulinum neurotoxins: current vaccination strategies and molecular immune recognition.

  2010cites this paper
• Optimization of the BoNT/A‐Hc expression in recombinant Escherichia coli using the Taguchi statistical method

  2010cites this paper
• Cloning, high level expression and immunogenicity of 1163-1256 residues of C-terminal heavy chain of C. botulinum neurotoxin type E.

  2010cites this paper
• Efficacy of a Potential Trivalent Vaccine Based on Hc Fragments of Botulinum Toxins A, B, and E Produced in a Cell-Free Expression System

  2010cites this paper
• The recombinant Hc subunit of Clostridium botulinum neurotoxin serotype A is an effective botulism vaccine candidate.

  2009cites this paper
• Chapter 31 – Botulism Vaccines and the Immune Response

  2009cites this paper
• Expression of the botulinum neurotoxin serotype D binding domain in Brevibacillus brevis and its evaluation as a candidate vaccine antigen in mice

  2009influential citation
• Generation of High-Titer Neutralizing Antibodies against Botulinum Toxins A, B, and E by DNA Electrotransfer

  2009cites this paper
• Protection with a recombinant Hc of Clostridium Botulinum neurotoxin serotype A from Escherichia coli as an effective subunit vaccine

  2009cites this paper
• Der seltsame Fall des Botulinum-Neurotoxins: chemische und biologische Modulierung des tödlichsten aller Gifte

  2008cites this paper
• The strange case of the botulinum neurotoxin: using chemistry and biology to modulate the most deadly poison.

  2008cites this paper
• Evaluation of a Recombinant Hc of Clostridium botulinum Neurotoxin Serotype F as an Effective Subunit Vaccine

  2008cites this paper
• Characterization of New Formalin-Detoxified Botulinum Neurotoxin Toxoids

  2008cites this paper
• Expression of a recombinant Hc of Clostridium botulinum neurotoxin

  2008cites this paper
• Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine.

  2007cites this paper
• High-level expression of the Hcc domain of Clostridium botulinum neurotoxin serotype A in Escherichia coli and its immunogenicity as an antigen.

  2007cites this paper
• Clostridial neurotoxins: structure-function led design of new therapeutics

  2006cites this paper
• Production of vaccines against leading biowarfare toxins can utilize DNA scientific technology.

  2005cites this paper
• Particulate delivery systems for biodefense subunit vaccines.

  2005cites this paper
• Medical defense against protein toxin weapons : review and perspective

  2005cites this paper
• Medical Defense Against Protein Toxin Weapons

  2005cites this paper
• Progress toward development of an inhalation vaccine against botulinum toxin

  2004cites this paper
• Cloning, high-level expression, single-step purification, and binding activity of His6-tagged recombinant type B botulinum neurotoxin heavy chain transmembrane and binding domain.

  2004cites this paper
• The C-terminus of botulinum neurotoxin type A light chain contributes to solubility, catalysis, and stability.

  2004cites this paper
• Basic immunological aspects of botulinum toxin therapy

  2004cites this paper
• Use of Biophysical Characterization in Preformulation Development of a Heavy-Chain Fragment of Botulinum Serotype B: Evaluation of Suitable Purification Process Conditions

  2004cites this paper
• Identifying and modulating disulfide formation in the biopharmaceutical production of a recombinant protein vaccine candidate.

  2003cites this paper
• Initial purification of recombinant botulinum neurotoxin fragments for pharmaceutical production using hydrophobic charge induction chromatography.

  2002cites this paper
• Epitope Mapping of Neutralizing Botulinum Neurotoxin A Antibodies by Phage Display

  2001cites this paper
• Expression of a tick toxin for the development of a canine vaccine

  2001cites this paper
• DNA Vaccination Using the Fragment C of Botulinum Neurotoxin Type A Provided Protective Immunity in Mice

  2000cites this paper
• Vaccination of mice with DNA encoding a large fragment of botulinum neurotoxin serotype A.

  2000cites this paper
• Development of vaccines for prevention of botulism.

  2000cites this paper
• DNA vaccination using the fragment C of botulinum neurotoxin type A provided protective immunity in mice.

  2000cites this paper
• Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins.

  1999cites this paper
• Production and purification of the heavy chain fragment C of botulinum neurotoxin, serotype A, expressed in the methylotrophic yeast Pichia pastoris.

  1998cites this paper
• DAMD 1794-C-4034 TITLE : Isolation and Characterization of Human Monoclonal Antibodies which Neutralize Botulinum Neurotoxin PRINCIPAL INVESTIGATOR :

  1998influential citation
• Development of recombinant vaccines for botulinum neurotoxin.

  1998cites this paper
• Production and purification of the heavy-chain fragment C of botulinum neurotoxin, serotype B, expressed in the methylotrophic yeast Pichia pastoris.

  1998cites this paper
• Purification, Potency, and Efficacy of the Botulinum Neurotoxin Type A Binding Domain from Pichia pastoris as a Recombinant Vaccine Candidate

  1998cites this paper
• Identification and characterization of a neutralizing monoclonal antibody against botulinum neurotoxin serotype F, following vaccination with active toxin.

  1997cites this paper
• Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries

  1997cites this paper
• Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli

  1995cites this paper